News & Updates
Filter by Specialty:
Brentuximab vedotin-chemo confers OS advantage over bleomycin-containing chemo for advanced HL
In the 6-year follow-up of the ECHELON-1 trial, a combination of the CD30-directed ADC* brentuximab vedotin and a chemotherapy (CT) regimen comprising doxorubicin, vinblastine, and dacarbazine (A+AVD), showed a survival advantage over a combination comprising the same CT regimen plus bleomycin (ABVD) in patients with previously untreated stage III or IV Hodgkin’s lymphoma (HL).
Brentuximab vedotin-chemo confers OS advantage over bleomycin-containing chemo for advanced HL
25 Oct 2022
Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
Among people living with HIV (PLHIV), immunization with a hepatitis B surface antigen (HBsAg)-based vaccine adjuvanted with a toll-like receptor (TLR)-9 agonist can induce a 100-percent seroprotection rate, according to a study presented at the recently concluded Virtual ID Week 2022.
Hepatitis B vaccine with TLR-9 agonist achieves high protection in people with HIV
25 Oct 2022
Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
The use of vedolizumab in the treatment of older patients with inflammatory bowel disease (IBD) appears to not only pose a higher risk of treatment failure but also offer no significant safety advantage when compared with tumour necrosis factor (TNF) antagonists, according to a study.
Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
25 Oct 2022
Tocilizumab trumps etanercept at suppressing RA joint erosion
Treatment with tocilizumab leads to better suppression of joint erosion progression as compared to etanercept in patients with rheumatoid arthritis (RA), reports a recent study.
Tocilizumab trumps etanercept at suppressing RA joint erosion
25 Oct 2022
Baseline HRQOL predicts survival in after radical prostatectomy
Baseline health-related quality of life (HRQOL) among patients with localized high-risk prostate cancer prior to radical prostatectomy is an important and a strong predictor of survival, suggests a study.
Baseline HRQOL predicts survival in after radical prostatectomy
24 Oct 2022
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
Sequential intravesical valrubicin and docetaxel prove to be an effective salvage treatment for patients with recurrent nonmuscle-invasive bladder cancer (NMIBC), a study has shown.
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
24 Oct 2022
Poor sleep quality, depression predict sexual dysfunction in women
Sexual dysfunction in women is associated with several factors, including senility, dissatisfaction with sleep, not having a partner, complaints of depression, low education, insufficient income, and worse perception of global health, according to a Brazil study.